InterVenn Biosciences

📍 South San Francisco, United States🗓 Founded 2017👥 63 employees💰 Last funded Jul 2020
Biotechnology Research🌐 intervenn.com
Website LinkedIn
InterVenn was co-founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist, and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso on the belief that no one should ever be blindsided by disease. We are focused on decoding the glycoproteome as a rich source of biological insight. Thanks to the use of artificial intelligence (AI), we have pioneered a proprietary technology platform, GlycoVision™, to tap into this layer of biology at a clinically meaningful scale. GlycoVision is capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. The GlycoVision platform is accessible to industry partners seeking to discover novel biomarkers from as little as 50 µL of serum or plasma.
3
Total investors
2
Early stage
1
Mid stage
0
Late stage
2017
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2018–2020 · investors recorded per year
2018220201
Recent (last 2y)Earlier
Frequently asked questions
Who invested in InterVenn Biosciences?
InterVenn Biosciences has 3 investors on record on gritt.io, including 2 early-stage backers, 1 mid-stage.
When did InterVenn Biosciences last raise funding?
The most recent investment in InterVenn Biosciences recorded on gritt.io was in July 2020.
When was InterVenn Biosciences founded?
InterVenn Biosciences was founded in 2017.
What industry is InterVenn Biosciences in?
InterVenn Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is InterVenn Biosciences based?
InterVenn Biosciences is headquartered in South San Francisco, United States.